

The Proton Collaborative Group's Research Portfolio: An Update from the PTCOG 2015 Presentation



Minesh Mehta MD ¹, Megan Dunn PhD ², Bradford Hoppe MD ³, George Laramore MD PhD ⁴, Andrew Chang MD ⁵, Carlos Vargas MD ⁶, William Hartsell MD ⁷

1 Miami Cancer Institute, 2 Proton Collaborative Group, 3 University of Florida, 4 University of Washington, 5 Scripps Proton Therapy Center, 6 Mayo Clinic, 7 Northwestern Medicine Chicago Proton Center

Introduction


The Proton Collaborative Group's (PCG) "Evaluation Tracking Project: the Prospective Chart Review of Patient Treated with Proton Therapy" (REG001-09) protocol allows for the collection and analysis of data to evaluate the diseases, treatment process, and outcomes for patients with various tumors treated primarily with proton beam therapy (PBT). This multi-institutional prospective trial was reported on in-depth, as well as the rest of the PCG research portfolio, at PTCOG's 2015 meeting. Current trends in enrollment and study activity are discussed as an update to the 2015 presentation.

Methods

As of December 2015, nine different centers have committed to participating in the REG001-09 protocol: an increase of two centers since mid-2015. Enrollment in this registry has been expanded to include all forms of radiation therapy, whereas participation was previously limited exclusively to patients treated with PBT. This was done to better facilitate the collection and reporting of comparative effectiveness data: a topic of increasing importance to PBT stakeholders and practitioners.

Results

The total number of subjects enrolled has increased from 4400 to 5700 since last reported, representing an enrollment rate of ~108 patients per month (previously reported as 66 patients per month). The majority of participants were enrolled in the prostate cancer category (n = 2583) and represented 45% of the research sample. However, this has decreased from the 48% reported in 2015, showing a rise in the number of non-prostate cases being treated and recorded. Growing subject categories include breast (up 48% from last year), sarcoma/chordoma (up 46% from last year), head and neck (up 41% from last year), and CNS (up 36% from last year).



Growing Subject Categories

Disease Area	Nov 2014	Nov 2015	% Increase
Breast	170	252	48%
CNS	442	602	36%
Head and Neck	354	508	41%
Sarcoma/chordoma	276	402	46%

Conclusion

In 2014, ASTRO called for PBT-treated patients to be enrolled on prospective multi-institutional registry trials, in order to generate superior evidence. The PCG continues to represent the largest and most mature entity in this category, and with the addition of photon patients, will be ideally positioned to generate CER outcomes and data.

PCG allows for members to use the data from the ongoing registry and trials to be used in independent research; resulting in 74 requests for use (up from 65 in 2015), presentations at various scientific meetings (ARS, ASTRO, AAPM, PTCOG, NASBS, ONS, ASCO, SIOP, ISPNO, AAMD, SOCR, and WCLC), and publications in six different journals.